> Although the polypill could produce substantial public health benefits, people in the United States are unlikely to find out anytime soon. This is because the

> Although the polypill could produce substantial public health benefits, people in the United States are unlikely to find out anytime soon. This is because the pill’s price is so low (≤$1 per tablet) and the cost of the large clinical trials required for FDA approval is so high, it is unattractive to investors. Here are two great articles on this topic by Ben Roin of MIT: Unpatentable Drugs and the Standards of Patentability: http://dash.harvard.edu/bitstream/handle/1/10611775/Unpatentable%20Drugs%20and%20the%20Standards%20of%20Patentability%20-%202009.pdf http://dash.harvard.edu/bitstream/handle/1/10611775/Unpatent... Solving the Problem of New Uses: http://dash.harvard.edu/bitstream/handle/1/11189865/Solving%20the%20Problem%20of%20New%20Uses%20.pdf http://dash.harvard.edu/bitstream/handle/1/11189865/Solving%...